phrykt

Annexon, Inc. (ANNX): who owns it and who trades it

As of Nov 16, 2026, ANNX insiders reported 9 open-market sales worth $286K and 13 purchases worth $12.4M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Ted Yednock (Vice president), with $70.3K. 4 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Annexon

From the latest filings

Overall: about as much buying as selling. Funds, insiders and famous investors were close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns ANNX

216 funds and institutions reported ANNX shares worth $1B at the end of Q2 2026. The largest holder is FMR LLC (Fidelity) with $111M.

10 largest owners, by value

FMR LLC (Fidelity)$111M
BlackRock, Inc.$77.3M
Redmile Group, LLC$67.8M
State Street Corp$56.1M
Bvf Inc$49.7M
Woodline Partners LP$39.5M
Vanguard Capital Management LLC$39.2M
Mak Capital One LLC$33.5M
Goldman Sachs Group Inc$33.3M
Siren, L.L.C.$25.5M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
FMR LLC (Fidelity)19.52M–$111M+84%
BlackRock, Inc.13.54M–$77.3M+24%
Redmile Group, LLC11.87M–$67.8M-18%
State Street Corp9.82M–$56.1M+42%
Bvf Inc8.70M–$49.7MNo change
Woodline Partners LP6.93M–$39.5M+196%
Vanguard Capital Management LLC6.87M–$39.2M+15%
Mak Capital One LLC5.86M–$33.5M+24%
Goldman Sachs Group Inc5.83M–$33.3M+171%
Siren, L.L.C.4.46M–$25.5M+13%
Bain Capital Life Sciences Investors, LLC4.44M–$25.3M-15%
Bellevue Group AG4.10M–$23.4M-21%
Geode Capital Management, LLC4.04M–$23.1M+20%
Mpm Bioimpact LLC3.54M–$20.2M–
Ameriprise Financial Inc3.51M–$20M+2%
Great Point Partners LLC3.50M–$20M+40%
Adage Capital Partners Gp, L.l.c.3.50M–$20M-19%
Morgan Stanley3.14M–$18M+15%
Palo Alto Investors LP2.95M–$16.8MNo change
Balyasny Asset Management L.P.2.83M–$16.2M-27%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, ANNX insiders reported $12.4M of open-market purchases and $286K of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$12.4M
13 trades, 4 people
Sales, 12 months
$286K
9 trades, 5 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 24, 2026
Filed Sep 25, 2026

Purchases and sales by month

$3.4M$3.4MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 24, 2026Douglas LoveCEOPurchase26,065$3.83$99.8KForm 4
May 28, 2026Muneer A SatterDirectorPurchase613,497$5.41$3.3MForm 4
May 11, 2026William H. CarsonDirectorPurchase plan8,000$5.78$46.2KForm 4
Apr 10, 2026William H. CarsonDirectorPurchase plan8,000$6.20$49.6KForm 4
Mar 10, 2026William H. CarsonDirectorPurchase plan8,000$5.67$45.4KForm 4
Mar 2, 2026Jamie DananbergCHIEF MEDICAL OFFICERSale5,820$5.43$31.6KForm 4
Mar 2, 2026Michael OverdorfVice presidentSale4,339$5.42$23.5KForm 4
Mar 2, 2026Ted YednockVice presidentSale5,566$5.42$30.2KForm 4
Mar 2, 2026Dean Richard ArtisVice presidentSale5,894$5.43$32KForm 4
Mar 2, 2026Jennifer LewCFOSale5,565$5.42$30.2KForm 4
Feb 18, 2026Dean Richard ArtisVice presidentSale5,290$5.10$27KForm 4
Feb 18, 2026Ted YednockVice presidentSale7,857$5.11$40.1KForm 4
Feb 18, 2026Michael OverdorfVice presidentSale6,225$5.10$31.7KForm 4
Feb 18, 2026Jennifer LewCFOSale7,851$5.11$40.1KForm 4
Dec 30, 2025William H. CarsonDirectorPurchase plan4,115$5.02$20.7KForm 4
Dec 1, 2025Jung ChoiDirectorPurchase33,000$4.19$138KForm 4
Dec 1, 2025William H. CarsonDirectorPurchase plan4,115$4.47$18.4KForm 4
Nov 21, 2025Muneer A SatterDirectorPurchase422,613$4.28$1.8MForm 4
Nov 20, 2025Muneer A SatterDirectorPurchase400,000$4.48$1.8MForm 4
Nov 19, 2025Muneer A SatterDirectorPurchase500,000$3.94$2MForm 4
Nov 18, 2025Muneer A SatterDirectorPurchase500,000$3.18$1.6MForm 4
Nov 17, 2025Muneer A SatterDirectorPurchase500,000$2.99$1.5MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Muneer A SatterDirector$12M–May 28, 2026
William H. CarsonDirector$180K–May 11, 2026
Jung ChoiDirector$138K–Dec 1, 2025
Douglas LovePRESIDENT AND CEO, Director$99.8K–Sep 24, 2026
Ted YednockEVP & CHIEF INNOVATION OFFICER–$70.3KMar 2, 2026
Jennifer LewEVP & CHIEF FINANCIAL OFFICER–$70.3KMar 2, 2026
Dean Richard ArtisEVP & CHIEF SCIENTIFIC OFFICER–$59KMar 2, 2026
Michael OverdorfEVP & CHIEF BUSINESS OFFICER–$55.3KMar 2, 2026
Jamie DananbergCHIEF MEDICAL OFFICER–$31.6KMar 2, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

ANNX short interest

28.98M ANNX shares are sold short. Over the last 12 reports the number of shares short went up 19%.

As of Oct 30, 2026, 28.98M ANNX shares were sold short, down 8.4% from the report before. At the average daily volume of 4.03M shares, buying them all back would take about 7.2 trading days (days to cover).

Shares short

28.98MMay 15Oct 3034.16M

Days to cover

7.2May 15Oct 3014.5

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 202628.98M–-8%4.03M7.2
Oct 15, 202631.63M–-1%3.07M10.3
Sep 30, 202632.01M–-3%3.60M8.9
Sep 15, 202632.87M–+2%2.81M11.7
Aug 31, 202632.09M–-2%2.52M12.7
Aug 14, 202632.58M–+6%2.47M13.2
Jul 31, 202630.77M–+3%2.94M10.4
Jul 15, 202629.83M–+1%5.19M5.7
Jun 30, 202629.60M–+12%5.46M5.4
Jun 15, 202626.39M–+2%2.84M9.3
May 29, 202625.83M–+6%2.65M9.7
May 15, 202624.29M–+4%1.83M13.3

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Annexon company events

Annexon filed 11 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.

  1. Nov 9, 2026ResultsReleased financial results. Filing
  2. Aug 12, 2026AnnouncementThe Company issued a press release titled “Annexon Expands Vonaprument Phase 3 Program in Geographic Atrophy to Add Month 24 Dual Primary Endpoint Complementing Month 15 Primary Endpoint and Launch Open-Label Extension Study.” A copy of the press release is attached as Exhibit 99.2 to this Current… Filing
  3. Aug 10, 2026LeadershipMuneer Satter, a member of the board of directors of Annexon, Inc., notified the Company of his resignation as a member of the Board and as a member of the audit committee of the Board and as chair of the nominating and corporate governance committee of the Board, effective immediately prior to the… Filing
  4. Aug 6, 2026AnnouncementAnnexon, Inc. issued a press release titled “Annexon Reports First U.S. and European Patient Cohort of GBS FORWARD Study Demonstrated Rapid, Positive Clinical Responses in All Tanruprubart Treated Patients Within One Week.” A copy of the press release is attached as Exhibit 99.1 to this Current… Filing
  5. Jul 30, 2026AgreementAnnexon, Inc. entered into a Loan and Security Agreement with Oxford Finance LLC, as collateral agent (in such capacity, the “Collateral Agent”), and certain lenders from time to time party thereto. Filing
  6. Jun 12, 2026VoteReported shareholder vote results. Filing
  7. May 7, 2026ResultsReleased financial results. Filing
  8. Mar 30, 2026ResultsReleased financial results. Filing
  9. Feb 17, 2026LeadershipThomas G. Wiggans, Chairman of the Board of Directors of Annexon, Inc., notified the Company of his intent to retire as a member of the Board and therefore not stand for reelection at the Company’s 2026 annual meeting of stockholders. Filing
  10. Jan 14, 2026AnnouncementShared information with investors. Filing
  11. Jan 12, 2026AnnouncementAnnexon, Inc. issued a press release titled “Annexon Accelerating Next Generation Targeted Immunotherapy Platform for Treatment of Neuroinflammatory Diseases with Multiple Registrational Milestones in 2026” announcing its 2026 strategic priorities and key milestones for its lead programs. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Annexon financials

Famous investors that hold ANNX

4 of the 50 well-known investors we track reported holding ANNX in their latest 13F filing. The largest position is Steve Cohen's, worth $14.3M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Steve Cohen · Point72 Asset ManagementQ3 20263.38M$14.3M0.0%+145%
Ken Griffin · Citadel AdvisorsQ3 20261.13M$4.8M0.0%+90%
Israel Englander · Millennium ManagementQ3 2026340,950$1.4M0.0%-71%
Jim Simons · Renaissance TechnologiesQ3 2026197,300$835K0.0%-57%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named ANNX in the last 120 days.

FiledHolderFormStake
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A2.3%
Nov 16, 2026BIOTECHNOLOGY VALUE FUND L P13G/A2.3%
Nov 5, 2026FMR LLC13G/A13.9%
Nov 5, 2026FMR LLC13G/A13.9%

Questions about Annexon, Inc. (ANNX) stock

Who owns the most ANNX stock?

The largest reported owner of Annexon, Inc. (ANNX) is FMR LLC (Fidelity). In total, 216 funds and institutions reported holding ANNX at the end of Q2 2026. See the largest owners.

Are ANNX insiders buying or selling?

In the last 12 months, ANNX insiders reported 13 open-market purchases worth $12.4M and 9 sales worth $286K. The latest trade was on Sep 24, 2026. See every trade.

What is the short interest in ANNX?

As of Oct 30, 2026, 28.98M ANNX shares were sold short, down 8.4% from the report before. At the average daily volume of 4.03M shares, buying them all back would take about 7.2 trading days (days to cover). See the history.

Which famous investors hold ANNX?

4 of the 50 well-known investors we track reported ANNX in their latest 13F filing, including Steve Cohen, Ken Griffin, Israel Englander. The largest position is worth $14.3M. See all holders.

Executive pay

Annexon's chief executive was paid a total of $3.6M for the year ended Dec 31, 2025, down 3% from $3.7M the year before. In the last 12 months, Annexon's executives and directors bought $12.4M of stock on the open market and sold $286K.

Chief executive, total pay$3.6MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$5.1MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$1.4MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.